论文部分内容阅读
探索大剂量尿激酶治疗视网膜中央动脉阻塞 (CRAO)的有效性和安全性。 6例单眼患有CRAO的病人 ,阻塞时间为 6h～ 6天(平均 3 7天) ,静脉滴注尿激酶每天 5 0万U ,总量 2 5 0万U ,治疗还包括前房穿刺、眼球按摩、口服醋氮酰胺、舌下含服硝酸异山梨酯和吸入 95 %O2 和 5 %CO2 混合气体及每天静脉滴注低分子右旋糖苷 5 0 0ml和金纳多 87 5mg。治疗前后检查眼底和视力。随访时间为 4～ 12个月。第一次用药后检查视力 :除 1例视力没有变化外 ,其余 5例视力出现不同程度的改善。出院时所有病人视力均有提高 ,并且达到或好于 0 0 5 ,3例大于 0 1,2例达到 1 0。最后随访视力 :6例大于 0 1,4例大于 0 2 ,2例视力恢复到发病前最好视力 1 2和 1 5。治疗期间未发现严重并发症。结果显示 ,大剂量尿激酶连续静脉滴注治疗CRAO能够重新建立视网膜血液循环和提高视力
To explore the efficacy and safety of high-dose urokinase in the treatment of central retinal artery occlusion (CRAO). Among the 6 patients with monocular CRAO, the obstruction time ranged from 6 h to 6 days (mean, 37 days). Intravenous infusion of urokinase was 500,000 U per day and the total dose was 25 million U. The treatment included anterior chamber puncture, Massage, oral acetazamide, sublingual sublingual isosorbide dinitrate and inhalation of 95% O2 and 5% CO2 mixed gas and daily intravenous infusion of low molecular weight dextran 500ml and goldase 87 5mg. Check the fundus and vision before and after treatment. Follow-up time was 4 to 12 months. Visual acuity after the first medication: In addition to one case of no change in visual acuity, the remaining five cases of visual acuity showed varying degrees of improvement. At discharge, all patients had improved visual acuity, and achieved or better than 0 0 5, 3 cases greater than 0 1, 2 cases reached 10. The final follow-up visual acuity: 6 cases were greater than 0 1,4 cases were greater than 0 2, 2 cases of visual acuity returned to the best before onset visual acuity 12 and 15. No serious complications were found during treatment. The results showed that high-dose urokinase continuous intravenous infusion of CRAO can re-establish retinal blood circulation and improve visual acuity